Eficacia y seguridad de eberconazol crema al 1% en el tratamiento de las micosis cutáneas: resultados de 2 estudios comparativos frente a clotrimazol crema al 1% y miconazol crema al 2%

Eberconazole is a topical, broad-spectrum imidazole derivative that has been shown to be effective and to have potent antimycotic activity against yeasts and fungi in preclinical studies, with optimal safety in phase I trials. Eberconazole causes no delayed hypersensitivity, photosensititvity or phototoxic effects and has little systemic absorption. To demonstrate the efficacy of eberconazole in the treatment of cutaneous mycoses, two comparative clinical trials of clotrimazole 1% cream versus miconazole 2% cream were carried out with identical design: both were multicenter, double-blind, randomized trials, with doses administered every 12 hours and a treatment duration of 4 weeks. Eberconazole demonstrated greater efficacy in the treatment of dermatophytoses and similar efficacy in the treatment of candidosis and pityriasis versicolor versus clotrimazole, and therapeutic equivalence versus miconazole. No differences in safety profile were found between the treatments.